Rut Klinger
YOU?
Author Swipe
View article: Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients
Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients Open
To predict outcome to combination bevacizumab (BVZ) therapy, we employed cell-free DNA (cfDNA) to determine chromosomal instability (CIN), nucleosome footprints (NF) and methylation profiles in metastatic colorectal cancer (mCRC) patients.…
View article: Analysis of Cell-Free DNA to Predict Outcome to Bevacizumab Combination Therapy in Metastatic Colorectal Cancer Patients
Analysis of Cell-Free DNA to Predict Outcome to Bevacizumab Combination Therapy in Metastatic Colorectal Cancer Patients Open
To predict outcome to combination bevacizumab (BVZ) therapy, we employed cell-free DNA (cfDNA) to determine chromosomal instability (CIN), nucleosome footprints (NF) and methylation profiles in metastatic colorectal cancer (mCRC) patients.…
View article: Abstract 5584: Analysis of cell free DNA to predict outcome to Bevacizumab combination therapy in metastatic colorectal cancer patients
Abstract 5584: Analysis of cell free DNA to predict outcome to Bevacizumab combination therapy in metastatic colorectal cancer patients Open
Purpose: Cell-free DNA (cfDNA) analysis in plasma is an emerging technique with numerous applications in oncology. We employed cfDNA to determine chromosomal instability (CIN), nucleosome footprints (NF) and methylation profiles in metasta…
Figure S3 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
High CDK7 protein expression is associated with poor prognosis in TNBC tissues
Supplementary Figure Legends from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
Supplementary Figure Legends
Figure S5 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
Combination treatment with THZ1 and ABT-263 shows synergistic effects in TNBC cells
Figure S1 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
High CDK7 mRNA expression is associated with poor prognosis in TNBC transcriptomic datasets
Figure S6 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
Validation of MYC and TP53 genes as prognostic markers in TNBC
Supplementary Figure Legends from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
Supplementary Figure Legends
Figure S6 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
Validation of MYC and TP53 genes as prognostic markers in TNBC
Data from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
Triple-negative breast cancer (TNBC) patients commonly exhibit poor prognosis and high relapse after treatment, but there remains a lack of biomarkers and effective targeted therapies for this disease. Here, we report evidence highlighting…
Data from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
Triple-negative breast cancer (TNBC) patients commonly exhibit poor prognosis and high relapse after treatment, but there remains a lack of biomarkers and effective targeted therapies for this disease. Here, we report evidence highlighting…
Figure S2 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
Antibody optimization for immunohistochemical assessment of CDK7
Figure S1 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
High CDK7 mRNA expression is associated with poor prognosis in TNBC transcriptomic datasets
Figure S2 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
Antibody optimization for immunohistochemical assessment of CDK7
Figure S3 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
High CDK7 protein expression is associated with poor prognosis in TNBC tissues
Figure S4 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
CDK7 and MYC mRNA expression in subsets of breast cancer
Figure S5 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
Combination treatment with THZ1 and ABT-263 shows synergistic effects in TNBC cells
Figure S4 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer Open
CDK7 and MYC mRNA expression in subsets of breast cancer
Prognostic value of the 6-gene OncoMasTR test in hormone receptor–positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors Open
Both OncoMasTR scores were significantly prognostic for DRFS and IDFS and provided additional prognostic information to the molecular and clinicopathological risk factors/tools assessed. OM was also the most accurate risk classification to…
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab Open
Purpose Patients with metastatic colorectal cancer (mCRC) have limited benefit from the addition of bevacizumab to standard chemotherapy. However, a subset probably benefits substantially, highlighting an unmet clinical need for a biomarke…
Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach Open
DNA methylation is altered in many types of disease, including metastatic colorectal cancer. However, the methylome has not yet been fully described in archival formalin-fixed paraffin embedded (FFPE) samples in the context of matched fres…
View article: Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer
Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer Open
Bevacizumab (bvz) is currently employed as an anti-angiogenic therapy across several cancer indications. Bvz response heterogeneity has been well documented, with only 10-15% of colorectal cancer (CRC) patients benefitting in general. For …
Vitamin D receptor as a target for breast cancer therapy Open
Considerable epidemiological evidence suggests that high levels of circulating vitamin D (VD) are associated with a decreased incidence and increased survival from cancer, i.e., VD may possess anti-cancer properties. The aim of this invest…